Phase 1 Trial of Recombinant Human Interleukin-1β (rhIL-1β), Carboplatin, and Etoposide in Patients with Solid Cancers: Southwest Oncology Group Study 8940

References

• Dinarello C A. Interleukin-1 and iittedeukiu-1 antagonism. Blood 1991; 77: 1627–1652
   PubMed Web of Science ®Google Scholar
• Platanias L C, Vogelzang N J. Biology, pathophysiology, and clinical prospects. Am J Med 1990; 89: 621–629
   PubMed Web of Science ®Google Scholar
• Oppenheim J J, Kovacs E J, Matsushima K, et al. There is more than one interleukin-1. Immunol Today 1986; 7: 45–50
   PubMedGoogle Scholar
• Neta N, Oppenheim J. IL-1: Can We Exploit Jekyll and Subjugate Hyde?. Biologic Therapy of Cancer Updates. Lippin-cott, Philadelphia October, 1992, No. 10
   Google Scholar
• Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472–475
   PubMed Web of Science ®Google Scholar
• Brugger W, Macklin W, Heimfeld S, et al. Ex vivo expansion of enriched peripheral blood CD34 + progenitor cells by stem cell factor, interleukin-1β (1L-1β), IL-6,1L-3, interferon-γ, erythropoietin. Blood 1993; 81: 2579–2854
   PubMed Web of Science ®Google Scholar
• Muench M O, Firpo M T, Moore M AS. Bone marrow transplantation with Interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 1993; 81: 3463–3473
   PubMed Web of Science ®Google Scholar
• Fibbe W E, Falkenburg J HF, Schaafsma M R. The hematopoietic activities of interleukin-1. Biolherapy 1989; 1: 263–271
   PubMedGoogle Scholar
• Zesbo K M, Yuschenkoff V N, Schiffer S, et al. Vascular endothelial cells and granulopoiesis: Interleukin-1 stimulates release of G-CSF andGM-CSF. Blood 1988; 71: 99–103
   PubMed Web of Science ®Google Scholar
• Neta R, Stein M B, Oppenheim J J, et al. The in vivo effects of interleukin-1. Bone marrow cells are induced to cycle after administration of interleukin-1. J Immunol 1987; 139: 1861–1866
   PubMed Web of Science ®Google Scholar
• Bagby G C, Jr. Interleukin-1 and hematopoiesis. Blood Rev 1989; 3: 152–161
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, William D E, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-y. J Immunol 1986; 136: 4487–4495
   PubMed Web of Science ®Google Scholar
• Kurland J L, Broxmeyer H E, Pelus L M, et al. Role for monocyte-macrophage-derived colony-stimulating factor and prostaglandin E in the positive and negative feedback control of myeloid stem cell proliferation. Blood 1978; 52: 388–407
   PubMed Web of Science ®Google Scholar
• O'Reilly M, Gamelli R L. Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5FU treatment. Exp Hematol 1990; 18: 974–978
   PubMed Web of Science ®Google Scholar
• Hino M, Tojo A, Miyazono K, et al. Effects of type β transforming growth factor on haematopoietic progenitor cells. Br J Haematol 1988; 70: 143–147
   PubMed Web of Science ®Google Scholar
• Keller J R, Mantel C, Sing G, et al. Transforming growth factor β 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3 dependent myeloid leukemia cell lines. J Exp Med 1988; 168: 737–744
   PubMed Web of Science ®Google Scholar
• Wolpe S D, Cerami A. Macrophage inflammatory proteins 1 and 2 members of a novel superfamily of cytokines. FASEB J 1989; 3: 2565–2573
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Sherry B, Lu L, et al. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood 1990; 6: 1110–1116
   Google Scholar
• Klimpel G R, Fleischmann R, Kimpel K D. Gamma interferon (Ifn γ) and Ifn β suppress murine myeloid colony formation (CFU-C): Magnitude of suppression is dependent upon level of colony-stimulating factor (CSF). J Immunol 1982; 129: 76–80
   PubMed Web of Science ®Google Scholar
• Raefsky E L, Platanias L C, Zoumbos N C, et al. Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 1985; 135: 2507–2512
   PubMed Web of Science ®Google Scholar
• Rigby W FC, Ball E D, Guyre P M, et al. The effect of recombinant DNA derived interferons on the growth of myeloid progenitor cells. Blood 1985; 65: 858–861
   PubMed Web of Science ®Google Scholar
• Graham G J, Pragnell I B. Negative regulators of hemopoieses—Current advances. Prog Growth Factor Res 1990; 2: 181–192
   PubMedGoogle Scholar
• Gasparetto C, Laver J, Abboud M, et al. Effects of interleukin-1 on hematopoietic progenitors: Evidence of stimulatory and inhibitory activities in a primate model. Blood 1989; 74: 547–550
   PubMed Web of Science ®Google Scholar
• Constine L S, Harwell B A, Keng P, et al. Interleukin 1 alpha stimulates hematopoiesis but not tumor cell proliferation and protects mice from lethal total body irradiation. Int J Radiat Oncol Biol Phys 1991; 20: 447–656
   PubMed Web of Science ®Google Scholar
• Moore M AS, Warren D J. Synergy of interleukin 1 and granulocyte colony-stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 1987; 84: 7134–7138
   PubMed Web of Science ®Google Scholar
• Eppstein D A, Kurahara C G, Bruni N A, et al. Prevention of dox-orubicin-induced hematotoxicity in mice by interleukin-1. Cancer Res 1989; 49: 3955–3960
   PubMed Web of Science ®Google Scholar
• Futami H, Jansen R, Macphee M J, et al. Chemoprotective effects of recombinant human IL-1α in cyclophosphamide-treated normal and tumor-bearing mice. J Immunol 1990; 145: 4121–4130
   PubMed Web of Science ®Google Scholar
• Stork L, Barczuk L, Kissinger M, et al. Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 1989; 73: 938–944
   PubMed Web of Science ®Google Scholar
• Fibbe W E, Van Der Meer J WM, Falkenburh J HF, et al. A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Hematol 1989; 17: 805–308
   PubMed Web of Science ®Google Scholar
• Hornung R, Loiigo D. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high dose cyclophosphamide therapy. Blood 1992; 80: 77–83
   PubMed Web of Science ®Google Scholar
• Damia G, Komschlies K, Wiltrout R. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: Protection from hematological and non-hematological toxicities. Cancer Res 1992; 52: 4082–4089
   PubMed Web of Science ®Google Scholar
• Casielli M, Block P, Talmadge J. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988; 140: 3830–3837
   PubMed Web of Science ®Google Scholar
• Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78(6)1420–1427
   PubMed Web of Science ®Google Scholar
• Smith J W, 2d, Urba W J, Curti B D, et al. The toxic and hematologic effects of intericukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 1141–1152
   PubMed Web of Science ®Google Scholar
• Tewari A, Buhles W C, Jr, Stames H F, Jr. Preliminary report: Effects of interleukin-1 on platelet counts. Lancet 1990; 336: 712–714
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Kudelka A P, Garrison L, et al. Effects of inter-leukin-1β on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994; 12: 707–714
   PubMed Web of Science ®Google Scholar
• Smith J W, II, Longo D L, Alvord G, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose car-boplatia N Engl J Med 1993; 328: 756–761
   Google Scholar
• Tanaka S, Tabuchi S, Watanabe K, et al. Preventive effects of interleukin 1 beta for ACNU-induced myelosuppression in malignant brain tumors: The experimental and preliminary clinical studies. J Neurooncol 1992; 14: 159–168
   PubMed Web of Science ®Google Scholar
• Iizumi T, Sato S., Iiyama T, et al. Recombinant human interleukin-1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers. Cancer 1991; 68: 1520–1523
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction of granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325(3)164–170
   PubMed Web of Science ®Google Scholar
• Schulchter L, Neuberg D, Atkins M, et al. A phase I study of intcrleukin-1 alpha (IL-1) and high dose cyclophosphamide (Cy) in patients with advanced cancer. Proc AmSoc Clin Oncol 1994; 13: 133, (abstract)
   Google Scholar
• Rinehart J, Delamater E W, Keville L, et al. Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system. Blood 1994; 84: 1457–1463
   PubMed Web of Science ®Google Scholar